Merck Expects 2024 Sales Of $63.6B-$64.1B Compared To Prior Guidance Of $63.4B-$64.4B And Consensus Of $64.162B

+1.30%

Merck & Co., Inc.

MRK

100.30

+1.30%

Full-Year 2024 Financial Outlook

The following table summarizes the company's full-year financial outlook.

	Full Year 2024
	Updated	Prior
Sales	$63.6 to $64.1 billion	$63.4 to $64.4 billion
Non-GAAP Gross margin	Approximately 81%	Approximately 81%
Non-GAAP Operating expenses2	$27.8 to $28.3 billion	$26.8 to $27.6 billion
Non-GAAP Other (income) expense, net	Approximately $100 million expense	Approximately $350 million expense
Non-GAAP Effective tax rate	16.0% to 17.0%	15.5% to 16.5%
Non-GAAP EPS	$7.72 to $7.77	$7.94 to $8.04
Share count (assuming dilution)	Approximately 2.54 billion	Approximately 2.54 billion

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.